BofA Cuts AbbVie (ABBV) Target While Maintaining Neutral View

AbbVie Inc. (NYSE:ABBV) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. BofA Cuts AbbVie (ABBV) Target While Maintaining Neutral View On December 15, BofA lowered the firm’s price target on AbbVie Inc. (NYSE:ABBV) to $233 from $248 and kept a Neutral rating. The firm said it sees “a relatively clean setup” for growth near the top end of the peer group, though that is offset by a premium valuation and limited late-stage pipeline catalysts. As part of the update, BofA shifted its valua ...